VACCINATION FOR PROTECTING POULTRY AGAINST A POULTRY PATHOGEN
The invention pertains to a vaccine comprising non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, for use in boosting an immune response in a poultry animal directed against the poultry pathogen by administering the vaccine mucosally to the poultry animal. The invention also pertains to a vaccine comprising a liquid pharmaceutically acceptable carrier, a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, as well as a method of boosting an immune response in a poultry animal, which immune response is directed against a poultry pathogen, by administering a vaccine mucosally to the poultry animal, the vaccine comprising a non-live antigen of the said poultry pathogen and a mucoadhesive adjuvant.
1 . A method of boosting an immune response in a poultry animal, which immune response is directed against a poultry pathogen, by administering a vaccine mucosally to the poultry animal, the vaccine comprising a non-live antigen of the said poultry pathogen and a mucoadhesive adjuvant.
2 . The method according to claim 1 , characterised in that the immune response in the poultry animal is a result of a natural infection with the poultry pathogen or the administration of a previous vaccine directed against the pathogen.
3 . The method according to claim 1 , characterised in that the immune response in the poultry animal is a result of a previous vaccination directed against the pathogen, by administering a previous vaccine parenterally or mucosally.
4 . The method according to claim 1 , characterised in that the immune response in the poultry animal is a result of a previous vaccination directed against the pathogen, by administering a previous vaccine comprising a non-live antigen of the poultry pathogen parenterally or by administering a previous vaccine comprising a live or non-live antigen of the poultry pathogen mucosally.
5 . The method according to claim 2 , characterised in that the vaccine comprising a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant is administered within 2-6 weeks after administration of the previous vaccine.
6 . The method according to claim 1 , characterised in that the vaccine is administered ocular (OC) and/or intranasally (IN).
7 . The method according to claim 1 , characterised in that the vaccine is administered by spraying the vaccine on the poultry animal.
8 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant has a molecular weight above 10,000 Da.
9 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant has a molecular weight above 10,000 Da and below 1,000,000 Da.
10 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant has a molecular weight above 10,000 Da and below 300,000 Da.
11 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant has a pKa value below 6.
12 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant has a pKa value between 3 and 5.
13 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant is chosen from an alginate and a polyalkylene oxide blockcopolymer.
14 . The method according to claim 1 , characterised in that the mucoadhesive adjuvant is present in the vaccine in an amount between 1 and 10% w/w.
15 . The method according claim 1 , characterised in that the poultry pathogen is a viral pathogen.
16 . The method according to claim 1 , characterised in that the poultry pathogen is chosen from Newcastle Disease Virus (NDV), Avian Reo Virus (ARV), Infectious bursal disease virus (IBDV) and Salmonella typhimurium.
17 . A vaccine comprising a liquid pharmaceutically acceptable carrier, a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant.
18 . (canceled)